According to researchers from Rice University, an amalgamation of drugs that impact mitochondria—commonly known as the powerhouse of the cells—might become the ideal weapon to battle acute myeloid leukemia. The new study was conducted by postdoctoral researcher Svetlana Panina and bioscientist Natasha Kirienko discovered that mitocans—which are anti-cancer drugs that aim mitochondria—are chiefly proficient at killing leukemia cells, particularly when mixed with a glycolytic inhibitor, while separating healthy blood cells in the same sample mostly unaffected. The study was published in the journal Cell Death & Disease by Nature. This study can pave new ways to customize treatment for people having leukemia.
Kirienko added, “We began with the idea of discovering an underlying link amid types of cancer and its sensitivity to particular kinds of chemotherapeutics. Our bioinformatics analysis—comprised 60 cell lines from 9 various cancer types—showed that leukemia cells are chiefly sensitive to mitochondrial damage.” The scientists exhibited the cell lines to manifold known mitocan molecules. They discovered a low dose of a mitocan or glycolytic inhibitor mixture killed all of the leukemia cell lines they analyzed at concentrations lesser than what was required to kill healthy cells. On the other hand, they stated that solid tumor cells—such as ovarian cancers—proved exceedingly resistant to mitocans.
On a related note, recently, a study showed that leukemia cells starved by targeting amino acids. Cancer cells use sugar at a greater rate compared to healthy cells, but they are also famished for amino acids, which are the building blocks of proteins and biomolecules. Scientists from Winship Cancer Institute of Emory University found a method to exploit that starving to selectively stop the growth of leukemia. The study was published in Nature Metabolism and researchers identified a transporter enzyme known as ASCT2—which consumes amino acids into cells. By deletion of the gene encoding this enzyme, the endurance of mice is prolonged with an aggressive type of leukemia AML (acute myeloid leukemia): from 45 Days to over 300 Days.
Being an experienced member of the team with an experience of 6 years, Nancy Byrd is a dynamic part of this organization. Having the intent to bring the latest information and innovations &invention from the Health field to the ordinary public in an understandable way got Nancy into the writing world. She writes about the numerous official approvals, new developments, drug discoveries, health programs & initiatives, and much more. Being a reading freak, Nancy, in spare time, reads book of genres suspense, inspirational, or thriller.